Twenty-five patients were treated with the combination of both substances. Patients have received once weekly infusions of WX-UK1 for three weeks at various fixed doses and daily capecitabine
The Phase II trial is designed as a randomized, double-blind, placebo- controlled, intent-to-treat, multi-center study to evaluate the safety and efficacy of CPP-109 as a treatment for cocaine
As part of the partnership, Calibrant will identify protein networks and novel therapeutic targets involved in the progression of the most common and aggressive primary brain cancer, glioblastoma
Arena also announced that preclinical investigation of MK-0354, a first generation niacin receptor agonist being evaluated for indications other than atherosclerosis, was discontinued for compound specific reasons. Jack
TransTech made an undisclosed one-time payment to Novo Nordisk for acquisition of the programs. Adnan Mjalli, TransTech’s founder, chairman and CEO, said: “We are extremely pleased to have
The study will evaluate OncoGel administered in combination with pre-operative chemoradiotherapy versus pre-operative chemoradiotherapy alone in 124 patients. The primary endpoint of the study is a blinded assessment
The primary objective of the multi-center clinical trial is to assess the overall response rate to the combination of bavituximab with carboplatin and paclitaxel, chemotherapy drugs commonly used
The lawsuit was filed in the US District Court of Florida, Jacksonville Division, alleging violations of state consumer protection statutes, breach of warranty, and unjust enrichment. The lawsuit
In addition to assuring a constant and ready supply to wholesale distributors and providing ordering instructions to all retail pharmacies, Aton Pharma is supporting Lacrisert with a reimbursement
Glumetza 1,000mg will be introduced to health-care professionals throughout the country by Biovail Pharmaceuticals Canada (BPC), the company’s Canadian sales and marketing division. Scott Smith, vice-president and general
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.